Education
About Us
Working with TipRanks
Follow Us
Mabion SA (DE:272)
FRANKFURT:272
272 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€1.93 - €3.86
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€32.97M
Enterprise Value€141.82M
Total Cash (Recent Filing)€23.69M
Total Debt (Recent Filing)€3.56M
Price to Earnings (P/E)15.8
Beta0.60
Next Earnings
Nov 04, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding16,162,327
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.99Price Target Upside0.00%
Rating ConsensusHold
Number of Analyst Covering1
272 FAQ
What was Mabion SA’s price range in the past 12 months?
Mabion SA lowest stock price was €1.93 and its highest was €3.85 in the past 12 months.
What is Mabion SA’s market cap?
Mabion SA’s market cap is €32.97M.
When is Mabion SA’s upcoming earnings report date?
Mabion SA’s upcoming earnings report date is Nov 04, 2025 which is in 35 days.
How were Mabion SA’s earnings last quarter?
Currently, no data Available
Is Mabion SA overvalued?
According to Wall Street analysts Mabion SA’s price is currently same.
Does Mabion SA pay dividends?
Mabion SA does not currently pay dividends.
What is Mabion SA’s EPS estimate?
Mabion SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mabion SA have?
Mabion SA has 16,162,327 shares outstanding.
What happened to Mabion SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Mabion SA?
Currently, no hedge funds are holding shares in DE:272
Company Description
Mabion SA
Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. Its products include MabionCD20 and MabionHER2. The company was founded in 2007 and is based in Konstantynów Lódzki, Poland.
Technical Analysis
Options Prices
Currently, No data available
---